Polycystic Kidney Disease Pipeline Review, H2 2015 Featuring 8 Companies & their Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/58cdcl/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease Prostate Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Polycystic Kidney Disease Prostate Cancer Overview
3. Therapeutics Development
4. Pipeline Products for Polycystic Kidney Disease Prostate Cancer - Overview
5. Pipeline Products for Polycystic Kidney Disease Prostate Cancer - Comparative Analysis
6. Polycystic Kidney Disease Prostate Cancer - Therapeutics under Development by Companies
7. Polycystic Kidney Disease Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
8. Polycystic Kidney Disease Prostate Cancer - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Polycystic Kidney Disease Prostate Cancer - Products under Development by Companies
13. Polycystic Kidney Disease Prostate Cancer - Products under Investigation by Universities/Institutes
14. Polycystic Kidney Disease Prostate Cancer - Companies Involved in Therapeutics Development

• DiscoveryBiomed, Inc.
• Endocyte, Inc.
• IC-MedTech, Inc.
• Ipsen S.A.
• Kadmon Corporation, LLC
• Metabolic Solutions Development Company, LLC
• Otsuka Holdings Co., Ltd.
• Synta Pharmaceuticals Corp.

For more information visit http://www.researchandmarkets.com/research/58cdcl/polycystic_kidney